Luminar Technologies Azioni (NASDAQ: LAZR)

Ultime notizie per Luminar Technologies (NASDAQ:LAZR) Azioni

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.

matrix-2953883

News

LAZR

Dopo un trimestre oltre le aspettative, il titolo del settore auto-tech registra un&#39;impennata significativa.

Oltre le aspettative: LAZR sbalordisce con i risultati del Q4 e sale del 55%

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Morgan Stanley analyst Brian Nowak maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $750 to $850.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Meta Platforms, Raises Price Target to $850

JP Morgan analyst Ryan Brinkman downgrades Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) from Overweight to Neutral and maintains the price target from $155 to $155.

Downgrades

JP Morgan Downgrades Avis Budget Gr to Neutral, Maintains Price Target to $155

Morgan Stanley analyst Carlos De Alba reinstates MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) with a Equal-Weight and announces $65 price target.

Initiation

Morgan Stanley Reinstates Equal-Weight on MP Materials, Announces $65 Price Target

Needham analyst Charles Shi maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and raises the price target from $110 to $115.

LRCX

Needham Maintains Buy on Lam Research, Raises Price Target to $115

Cryptocurrency markets are up on Thursday, reversing a short-lived dip following a &#8216;hawkish&#8217; press conference by Federal Reserve Chair jerome Powell.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$118,477.01</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,847.15</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$181.23</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.16</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2229</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001309</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction increased by 7.2% and 4.2%, respectively. Daily active addresses moved higher by 0.4% and 25.8%, respectively.</li>
<li>Coinglass data shows 136,384 traders were liquidated in the past 24 hours for $423.35 million.</li>
<li>SoSoValue data shows net intflows of $47.04 million into spot Bitcoin ETFs on Wednesday. Spot Ethereum ETFs saw net inflows of $5.8 million.</li>
</ul>
Trader Notes: Crypto trader George <a href="https://x.com/George1Trader/status/1950857221807493266">observed</a> Bitcoin dipping slightly more than anticipated but successfully retesting its range lows. It now appears &#8220;primed&#8221; for a breakout toward $121,000 and beyond.
Michael van de Poppe noted Bitcoin experienced a brief liquidity sweep after the FOMC, but it quickly reclaimed its range and is looking strong and well-positioned for a move to new all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Small liquidity sweep on <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> after FOMC. It&#39;s back up in the range and looking extremely primed to be breaking upwards to a new ATH. <a href="https://t.co/YlsukDGLbg">pic.twitter.com/YlsukDGLbg</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1950837207062794263?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1950826847568089382">highlighted</a> that Ethereum continues to respect Fibonacci retracement levels. While in 2021 price often bounced sharply at the 0.618, this cycle sees deeper retracements, often toward 0.786 or equal lows, before reversing.
CW <a href="https://x.com/CW8900/status/1950804735755456564">pointed</a> out that Solana could rally to $270 but must first clear heavy resistance near $203 to unlock further upside.
Galaxy identified a broadening wedge pattern in XRP, which continues to hold support around $3. This pattern often precedes sharp price discovery moves.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> is forming a &#39;&#39;broadening wedge&#39;&#39; while holding the $3 floor. Price discovery should resume soon. <a href="https://t.co/qbZCmiwUlQ">pic.twitter.com/qbZCmiwUlQ</a>
&mdash; Galaxy (@galaxyBTC) <a href="https://twitter.com/galaxyBTC/status/1950764232686948708?ref_src=twsrc%5Etfw">July 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1950829787641192804">flagged</a> a TD Sequential buy signal on the daily chart, suggesting a fresh leg up could already be underway across key altcoins.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46727850/bitcoin-to-hit-200000-by-year-end-bitwises-matt-hougan-maintains">Bitcoin To Hit $200,000 By Year-End, Bitwise&#8217;s Matt Hougan Maintains</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin Steadies At $118,000 As Ethereum, XRP, Dogecoin Push Higher

Morgan Stanley analyst Erin Wright downgrades Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) from Overweight to Equal-Weight and lowers the price target from $249 to $154.

ALGN

Morgan Stanley Downgrades Align Technology to Equal-Weight, Lowers Price Target to $154

Atco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACO#TSX">ACO</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.89 by 1.12 percent. This is a 95.65 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $1.158 billion which missed the analyst consensus estimate of $1.240 billion by 6.61 percent. This is a 4.14 percent increase over sales of $1.112 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

TSX:ACO

TSX:ACO.X

Atco Q2 Adj. EPS $0.90 Beats $0.89 Estimate, Sales $1.158B Miss $1.240B Estimate

Jefferies analyst Christopher LeFemina upgrades Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Hold to Buy and raises the price target from $135 to $170.

Upgrades

Jefferies Upgrades Nucor to Buy, Raises Price Target to $170

Needham analyst James Ricchiuti maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $43 to $56.

TTMI

Needham Maintains Buy on TTM Technologies, Raises Price Target to $56

Morgan Stanley analyst Joseph Moore upgrades Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) from Underweight to Equal-Weight and raises the price target from $74 to $100.

Morgan Stanley Upgrades Teradyne to Equal-Weight, Raises Price Target to $100

<ul>
<li>This agreement marks a major step forward from the non-binding heads of agreement signed in June 2025 and underscores Sempra Infrastructure and JERA's shared commitment to supporting energy security and a lower carbon future through stable, long-term LNG supply.</li>
<li>The proposed Port Arthur LNG Phase 2 project is competitively positioned and is under active marketing and development. Future phases are also in the early development stage.</li>
<li>The project has received all its key permits and is expected to include two liquefaction trains capable of producing approximately 13 Mtpa of LNG, which could increase the total liquefaction capacity of the Port Arthur LNG facility from approximately 13 Mtpa for Phase 1 to up to approximately 26 Mtpa.</li>
<li>In September 2023 the project received authorization from the Federal Energy Regulatory Commission. In July 2024, Sempra Infrastructure announced that Bechtel had been selected for a fixed-price engineering, procurement and construction contract for the project. More recently, the project received authorization in May 2025 from the U.S. Department of Energy to export U.S. LNG to countries that do not have a free-trade agreement with the U.S.</li>
<li>The Port Arthur LNG Phase 1 project, which is currently under construction, is expected to achieve commercial operation in 2027 and 2028 for trains 1 and 2, respectively.</li>
<li>The development of the Port Arthur LNG Phase 2 project remains subject to a number of risks and uncertainties, including completing the required commercial agreements, securing and/or maintaining all necessary permits, obtaining financing and reaching a final investment decision, among other factors. &nbsp;</li>
</ul>

Commodities

Contracts

Markets

Sempra Infrastructure, A Subsidiary Of Sempra, And JERA Announced A 20-year Sale And Purchase Agreement For The Supply Of 1.5M Tonnes Per Annum Of Liquefied Natural Gas Offtake From The Port Arthur LNG Phase 2 Development Project In Jefferson County, Texas

Canaccord Genuity analyst Austin Moeller upgrades Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) from Hold to Buy and raises the price target from $6.75 to $10.5.

HDSN

Canaccord Genuity Upgrades Hudson Technologies to Buy, Raises Price Target to $10.5

Morgan Stanley analyst Michael Ulz upgrades Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) from Equal-Weight to Overweight and raises the price target from $55 to $62.

IONS

Morgan Stanley Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $62

Keybanc analyst Eric Heath downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Overweight to Sector Weight.

PANW

Keybanc Downgrades Palo Alto Networks to Sector Weight

NAMM

Namib Minerals Issues Corporate Update Following Nasdaq Listing And Closing Bell Ceremony, Accelerates Redwing Dewatering And Mazowe Infrastructure Upgrades

Keybanc analyst Jackson Ader upgrades Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from Sector Weight to Overweight and announces $630 price target.

MSFT

Keybanc Upgrades Microsoft to Overweight, Announces $630 Price Target

<ul>
<li>As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treated with NXP800 at the target dose of 75 mg/day, administered intermittently or daily, with data available for 13 patients. Overall, treatment resulted in 2 patients achieving partial response (unconfirmed) and 3 achieving stable disease. Thrombocytopenia, a key toxicity identified early in the study, was successfully managed following the switch to intermittent dosing. The company will not pursue further development of NXP800 in ovarian cancer but, in the coming months, will evaluate the feasibility of development opportunities for NXP800 in other cancer types, such as endometrial and prostate cancers, in which the patients' performance status and other characteristics may allow treatment with NXP800 to be more impactful.</li>
<li>With the recent successful completion of the NXP900 DDI study, which supports the potential combination of NXP900 with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer (NSCLC), and now the successful completion of the Phase 1a dose-escalation study, the Company is poised for the start of the Phase 1b study of NXP900, expected in the coming weeks. The Phase 1a dose escalation study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NXP900 in patients with advanced solid tumors (all comers). In this study, a dose range of 20 to 300 mg/day was evaluated and the dose limiting toxicity dose level was not reached. As presented by the study investigators at the 2025 American Association for Cancer Research (AACR) conference, the most common treatment emergent adverse events were mainly gastrointestinal-related and mild to moderate in intensity; systemic exposure to NXP900 increased with increased doses and a robust pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was elicited at doses of 150 mg/day and higher, suggesting a potentially wide therapeutic window. The final data from the study is expected to be presented at a future medical/scientific conference.</li>
<li>Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types</li>
<li>NXP900 successfully completed a clinical drug-drug interaction (DDI) study in healthy volunteers and the Phase 1a dose escalation study; initiation of the NXP900 Phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents expected in the coming weeks</li>
</ul>

Biotech

Health Care

General

NVCT

Nuvectis Pharma Shared Final Clinical Data Update From The Phase 1b Study Of NXP800 In Recurrent, Platinum Resistant, ARID1a-mutated Ovarian Cancer And Reported On The Progress Towards The Initiation Of The Phase 1b Program For NXP900

Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.01) by 2200 percent. This is a 116.2 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $890.100 million which missed the analyst consensus estimate of $944.200 million by 5.73 percent. This is a 14.58 percent decrease over sales of $1.042 billion the same period last year.

Peabody Energy Q2 EPS $(0.23) Misses $(0.01) Estimate, Sales $890.100M Miss $944.200M Estimate

DSV (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSDVY#OTC">DSDVY</a>) reported quarterly earnings of $0.75 per share. This is a 21.87 percent decrease over earnings of $0.96 per share from the same period last year. The company reported $9.418 billion in sales this quarter. This is a 58.58 percent increase over sales of $5.939 billion the same period last year.

DSDVY

DSV Q2 EPS $0.75 Down From $0.96 YoY, Sales $9.418B Up From $5.939B YoY

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $19 to $15.

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

Press Releases

Luminar Technologies, Inc. Investors: Company Investigated by the Portnoy Law Firm

LAZR Investors Have Opportunity to Lead Luminar Technologies, Inc. Securities Fraud Lawsuit

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Luminar Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LAZR

Legal

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf

LAZR Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Luminar Technologies, Inc.

Penny Stocks

LAZR Investors Have Opportunity to Lead Luminar Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LAZR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Luminar Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Luminar Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LAZR Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Luminar Technologies, Inc. Class Action

Comments

Luminar Technologies

Notizie

Ultime notizie per Luminar Technologies (NASDAQ:LAZR) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO